ARTICLE | Clinical News
Actimab-A regulatory update
January 5, 2015 8:00 AM UTC
FDA granted Orphan Drug designation to Actimab-A from Actinium to treat acute myelogenous leukemia (AML) in patients ages =60. The product -- actinium-225 attached to the anti- CD33 mAb lintuzumab (Hu...